title: Inulin-Type β2-1 Fructans have Some Effect on the Antibody Response to Seasonal Influenza Vaccination in Healthy Middle-Aged Humans.
abstract: β2-1 fructans are prebiotics and, as such, may modulate some aspects of immune function. Improved immune function could enhance the host's ability to respond to infections. There is limited information on the effects of β2-1 fructans on immune responses in humans. The objective of the study was to determine the effect of a specific combination of long-chain inulin and oligofructose (Orafti(®) Synergy1) on immune function in middle-aged humans, with the primary outcome being response to seasonal influenza vaccination. Healthy middle-aged humans (45-63 years of age) were randomly allocated to consume β2-1 fructans in the form of Orafti(®) Synergy1 (8 g/day; n = 22) or maltodextrin as control (8 g/day; n = 21) for 8 weeks. After 4 weeks, participants received the 2008/2009 seasonal influenza vaccine. Blood and saliva samples were collected prior to vaccination and 2 and 4 weeks after vaccination. They were used to measure various immune parameters. The primary outcome was the serum concentration of anti-vaccine antibodies. Serum antibody titers against the vaccine and vaccine-specific immunoglobulin concentrations increased post-vaccination. Antibodies to the H3N2-like hemagglutinin type 3, neuraminidase type 2-like strain were higher in the Synergy1 group (P = 0.020 for overall effect of treatment group), as was serum vaccine-specific IgG1 2 weeks post-vaccination (P = 0.028 versus control). There were no other differences between groups in antibody titers or anti-vaccine immunoglobulin concentrations, in blood immune cell phenotypes, or in a range of immune parameters. It is concluded that Orafti(®) Synergy1, a combination of β2-1 fructans, can enhance some aspects of the immune response in healthy middle-aged adults, but that this is not a global effect.
authors.affiliation: Human Development and Health Academic Unit, Faculty of Medicine, Southampton General Hospital, University of Southampton , Southampton , UK.
authors.forename: Amy R
authors.initials: AR
authors.lastname: Lomax
authors.affiliation: Human Development and Health Academic Unit, Faculty of Medicine, Southampton General Hospital, University of Southampton , Southampton , UK.
authors.forename: Lydia V Y
authors.initials: LV
authors.lastname: Cheung
authors.affiliation: Human Development and Health Academic Unit, Faculty of Medicine, Southampton General Hospital, University of Southampton , Southampton , UK.
authors.forename: Paul S
authors.initials: PS
authors.lastname: Noakes
authors.affiliation: Human Development and Health Academic Unit, Faculty of Medicine, Southampton General Hospital, University of Southampton , Southampton , UK.
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Miles
authors.affiliation: Human Development and Health Academic Unit, Faculty of Medicine, Southampton General Hospital, University of Southampton , Southampton , UK ; National Institute for Health Research Southampton Biomedical Research Centre, Southampton General Hospital, University Hospital Southampton NHS Foundation Trust and University of Southampton , Southampton , UK ; Department of Biological Sciences, Faculty of Science, King Abdulaziz University , Jeddah , Saudi Arabia.
authors.forename: Philip C
authors.initials: PC
authors.lastname: Calder
keywords: antibodies; immune response; oligofructose; prebiotic; vaccination